Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04725903
Other study ID # STUDY00000329
Secondary ID NCI-2020-07113RA
Status Recruiting
Phase N/A
First received
Last updated
Start date February 1, 2021
Est. completion date May 1, 2025

Study information

Verified date June 2023
Source Emory University
Contact Pretesh Patel, MD
Phone 404-778-3473
Email pretesh.patel@emory.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase II trial investigates whether proton radiation therapy directed to the prostate tumor, pelvic, and para-aortic lymph nodes, is an effective way to treat patients with high-risk or lymph node positive prostate cancer who are receiving radiation therapy, and if it will result in fewer gastrointestinal and genitourinary side effects. Proton beam therapy is a new type of radiotherapy that directs multiple beams of protons (positively charged subatomic particles) at the tumor target, where they deposit the bulk of their energy with essentially no residual radiation beyond the tumor. By reducing the exposure of the healthy tissues and organs to radiation in the treatment of prostate cancer, proton therapy has the potential to better spare healthy tissue and reduce the side effects of radiation therapy.


Description:

PRIMARY OBJECTIVE: I. To determine the rate of acute grade 2+ gastrointestinal toxicity compared to historical photon treatments. SECONDARY OBJECTIVES: I. To determine the rate of acute grade 2+ genitourinary toxicity compared to historical photon treatments. II. To assess the feasibility of extended-field proton irradiation of high-risk prostate. III. To demonstrate safety of proton therapy followed by high dose rate (HDR) boost. IV. To determine patient-reported outcomes (PROs) of toxicity. OUTLINE: Patients undergo conventionally fractionated proton beam therapy daily on Monday-Friday. Patients may receive a high-dose rate brachytherapy boost. After completion of study treatment, patients are followed up at 1, 3, 6, 9 and 12 months, and 1.5, 2, 2.5, and 3 years.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date May 1, 2025
Est. primary completion date May 1, 2024
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Pathologically confirmed high-risk prostate cancer fulfilling any one of the following criteria: - Gleason grade 8 or higher - cT3b (seminal vesicle involvement) or cT4 - Prostate specific antigen [PSA] > 20 (or PSA >10 if on finasteride) - Clinically or pathologically positive regional lymph nodes within the inguinal, external iliac, internal iliac, obturator, peri-rectal, pre-sacral, common iliac, or lower para-oaortc (inferior to the L2-L3 interspace) basins - Zubrod performance status 0-2 - Complete blood cell (CBC)/differential obtained within 90 days prior to registration on study - Absolute neutrophil count (ANC) >= 1,500 cells/mm^3 (obtained within 60 days prior to registration on study) - Platelets >= 100,000 cells/mm^3 (obtained within 60 days prior to registration on study) - Hemoglobin >= 8.0 g/dl (obtained within 60 days prior to registration on study) (Note: The use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 8.0 g/dl is acceptable) - Patient must be able to provide study specific informed consent Exclusion Criteria: - Absence of bone metastasis by bone scan or metabolic imaging (e.g. NaF PET, FACBC PET, PSMA PET, etc.) within 90 days prior to registration. - Absence of distant lymph node metastasis by CT and/or MRI within 90 days prior to registration. - Previous radical surgery (prostatectomy) or cryosurgery for prostate cancer - Prior radiotherapy, including brachytherapy, to the region of the study cancer that would result in overlap of radiation therapy fields - Uncontrolled intercurrent illness including, but not limited to, inflammatory bowel disease, human immunodeficiency virus infection, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

Study Design


Related Conditions & MeSH terms

  • Prostatic Neoplasms
  • Stage III Prostate Cancer AJCC v8
  • Stage IIIA Prostate Cancer AJCC v8
  • Stage IIIB Prostate Cancer AJCC v8
  • Stage IIIC Prostate Cancer AJCC v8

Intervention

Radiation:
High-Dose Rate Brachytherapy
Receive high-dose rate brachytherapy boost
Proton Beam Radiation Therapy
Undergo proton beam therapy
Other:
Quality-of-Life Assessment
Ancillary studies
Survey Administration
Ancillary studies

Locations

Country Name City State
United States Emory University Hospital/Winship Cancer Institute Atlanta Georgia

Sponsors (2)

Lead Sponsor Collaborator
Emory University National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acute grade 2+ gastrointestinal (GI) toxicity The rate of grade 2+ gastrointestinal toxicity within 30 days of receiving radiation therapy (RT) will be measured. It will be compared to the theorized reduction to 24% toxicity using the exact binomial test. Assessments are based on version 5 Common Terminology Criteria for Adverse Events (CTCAE), and the worst severity of GI toxicity will be assessed. Up to 3 years
Secondary Acute grade 2+ genitourinary (GU) toxicity rate The rate of grade 2+ genitourinary toxicity within 30 days of receiving radiation therapy (RT) will be measured. Assessments are based on version 5 CTCAE, and the worst severity of GU toxicity will also be assessed. Up to 3 years
Secondary Optimal frequency of cone beam computed tomography (CT) Will determine the optimal frequency of cone beam CT during treatment and assess subsequent need for adaptive re-planning. The feasibility of extended-field proton irradiation of high-risk prostate cancer will be estimated using a re-planning rate of less than 10%. The re-planning rate will be estimated as binary variable, yes or no. The exact 95% confidence interval (CI) around the 10 % re-planning count based on the binomial distribution for the estimated 30 patients will be used (0.021-0.265). The study will be deemed feasible if the observed rate is not higher than the upper bound of the estimated 95% CI. Through study completion, an average of 1 year
Secondary Patient reported health related quality of life (QOL) - PRO-CTCAU GI Assessed using Patient Reported Outcomes-CTCAE GI toxicity Up to 3 years
Secondary Patient reported health related quality of life (QOL) - PRO-CTCAU GU Assessed using Patient Reported Outcomes-CTCAE GU toxicity Up to 3 years
Secondary Patient reported health related quality of life (QOL) - IPSS International Prostate Symptom Score (IPSS) Up to 3 years
Secondary Patient reported health related quality of life (QOL) - EPIC-CP Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) Up to 3 years
Secondary Chronic GI Toxicity The rate of any grade gastrointestinal toxicity occurring after 90 days from the completion of radiation therapy(RT). Assessments are based on version 5 Common Terminology Criteria for Adverse Events (CTCAE), and the worst severity of GI toxicity will be assessed. Up to 3 years
Secondary Chronic GU Toxicity The rate of any grade genitourinary toxicity occurring after 90 days from the completion of radiation therapy(RT). Assessments are based on version 5 Common Terminology Criteria for Adverse Events (CTCAE), and the worst severity of GU toxicity will be assessed. Up to 3 years
Secondary Biochemical failure Assessed by the Phoenix definition (prostate specific antigen [PSA] >= 2 ng/ml over the nadir PSA). Baseline up to pre-RT
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03218826 - PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery Phase 1
Recruiting NCT04981834 - Robot-Assisted Radical Prostatectomy With or Without Vesicopexy in Patients With Prostate Cancer N/A
Completed NCT04976257 - Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion Early Phase 1
Recruiting NCT06173362 - Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer Phase 2
Suspended NCT03899987 - Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery Phase 2
Active, not recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1
Not yet recruiting NCT06129851 - Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer Phase 2
Not yet recruiting NCT05487846 - Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation N/A
Recruiting NCT05946213 - Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer Phase 3
Active, not recruiting NCT03570827 - Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy Phase 2
Recruiting NCT03987386 - Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer Phase 3
Not yet recruiting NCT06325046 - Evaluating Changes in Quality of Life After Near Margin-less Adaptive Radiation Therapy Compared to Standard Stereotactic Ablative Body Radiotherapy in Localized Prostate Cancer N/A
Recruiting NCT04134260 - Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer Phase 3
Completed NCT03177460 - Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer Phase 1
Active, not recruiting NCT05320406 - RElugolix VErsus LeUprolide Cardiac Trial Phase 4
Completed NCT04067960 - Pharmacogenomics Testing in Directing the Optimal Use of Supportive Care Medications in Patients With Stage III-IV Cancer Early Phase 1
Suspended NCT04037254 - Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer Phase 2
Recruiting NCT05869682 - Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy Phase 2
Recruiting NCT06389786 - Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer N/A
Recruiting NCT05877144 - Low-Intensity Shockwave Therapy to Treat Erectile Dysfunction and Preserve Erectile Function After Prostate Cancer Surgery N/A